Impedimed (ASX:IPD) Other Operating Expense: A$14.24 Mil (TTM As of Dec. 2025)


What is Impedimed Other Operating Expense?

Impedimed ASX:IPD Other Operating Expense is A$14.24 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Impedimed's Other Operating Expense for the six months ended in Dec. 2025 was A$6.19 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$14.24 Mil.

Impedimed's quarterly Other Operating Expense increased from Dec. 2024 (A$4.84 Mil) to Jun. 2025 (A$8.05 Mil) but then declined from Jun. 2025 (A$8.05 Mil) to Dec. 2025 (A$6.19 Mil).

Impedimed's annual Other Operating Expense declined from Jun. 2023 (A$12.13 Mil) to Jun. 2024 (A$10.20 Mil) but then increased from Jun. 2024 (A$10.20 Mil) to Jun. 2025 (A$12.89 Mil).

Impedimed Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Impedimed's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impedimed Other Operating Expense Chart

Impedimed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.40 9.41 12.13 10.20 12.89

Impedimed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.12 5.08 4.84 8.05 6.19

Impedimed Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$14.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of A$14.24 Mil mean?
Impedimed (ASX:IPD) has a Other Operating Expense of A$14.24 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Impedimed and its competitors.
Is Impedimed's Other Operating Expense too high?
Impedimed's current Other Operating Expense is A$14.24 Mil.
How does Impedimed's Other Operating Expense compare to ABT and SYK?
Impedimed's Other Operating Expense of A$14.24 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Impedimed and its competitors. Impedimed's current Other Operating Expense is A$14.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 92.5% below its estimated fair value. The current Other Operating Expense is A$14.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Other Operating Expense is A$14.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impedimed Business Description

Other Exchanges IPDQF:USA
Address 5900 Pasteur Court, Suite 125, Carlsbad, CA, USA, 92008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.